Vincerx Pharma, Inc. (VINC)
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies.
Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
|CEO||Dr. Ahmed M. Hamdy M.D.|
260 Sheridan Avenue, Suite 400
Palo Alto, California 94306
|Fiscal Year||January - December|
|Dr. Ahmed M. Hamdy M.D.||Founder, Chairman and Chief Executive Officer|
|Tom C. Thomas J.D.||Founder, General Counsel and Chief Legal Officer|
|Dr. Raquel E. Izumi Ph.D.||Founder, President, Chief Operating Officer, Secretary and Director|
|Dr. John C. Byrd M.D.||Founder and Chairman of Scientific Advisory Board|
|Alexander A. Seelenberger M.B.A., MBA||Chief Financial Officer|
|Dr. Hans-Georg Lerchen Ph.D.||Chief Scientific Officer|
|Melissa Merrick SPHR||Senior Director of People and Culture|
|Dr. David Nganele M.B.A., Ph.D.||Head of Early Development|
|Dr. Beatrix Stelte-Ludwig Ph.D.||Executive Chief Development Officer|
Latest SEC Filings
|Nov 14, 2023||10-Q||Quarterly Report|
|Nov 14, 2023||8-K||Current Report|
|Sep 15, 2023||8-K||Current Report|
|Aug 7, 2023||8-K||Current Report|
|Aug 7, 2023||10-Q||Quarterly Report|
|Jun 20, 2023||8-K||Current Report|
|May 30, 2023||8-K||Current Report|
|May 11, 2023||8-K||Current Report|
|May 11, 2023||10-Q||Quarterly Report|
|Apr 12, 2023||ARS||Filing|